Climb Bio, Inc.
NASDAQCLYM short interest surges 30% in one day to 11% of float, with utilization jumping to 90% as availability plummets to 16%.
Snapshot as of 29 Jul 2026
Climb Bio enters the back half of June with a 15% weekly gain, an unusually crowded call-side options book, and a wave of analyst conviction that stands in sharp contrast to a pipeline still in early clinical…
Climb Bio enters the week with the most notable analyst activity it has seen since its rebranding, as a fresh initiation from Guggenheim sets a price target that stands well above the rest of the Street. The analyst…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CLYM — free to start on ORTEX.
Sign up for free →Open CLYM on ORTEX